Nevro Corp. (NYSE:NVRO – Get Free Report) has been assigned an average rating of “Reduce” from the fourteen research firms that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating and eleven have assigned a hold rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $10.63.
Several research firms recently commented on NVRO. Wells Fargo & Company downgraded Nevro from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $13.00 to $5.50 in a research note on Wednesday, August 7th. Robert W. Baird cut their price target on Nevro from $11.00 to $8.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Piper Sandler lowered their price objective on Nevro from $12.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday, August 7th. Truist Financial cut their target price on shares of Nevro from $10.00 to $5.50 and set a “hold” rating for the company in a research report on Thursday, August 8th. Finally, Royal Bank of Canada lowered their price target on shares of Nevro from $16.00 to $7.00 and set a “sector perform” rating on the stock in a research report on Wednesday, August 7th.
Get Our Latest Analysis on Nevro
Institutional Inflows and Outflows
Nevro Stock Performance
NVRO stock opened at $4.72 on Monday. The business has a 50 day moving average of $7.28 and a 200-day moving average of $10.06. The firm has a market cap of $175.96 million, a PE ratio of -2.06 and a beta of 0.95. Nevro has a 12-month low of $4.38 and a 12-month high of $22.64. The company has a quick ratio of 3.53, a current ratio of 4.77 and a debt-to-equity ratio of 0.66.
Nevro (NYSE:NVRO – Get Free Report) last announced its earnings results on Tuesday, August 6th. The medical equipment provider reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.10. The firm had revenue of $104.16 million during the quarter, compared to analyst estimates of $107.11 million. Nevro had a negative return on equity of 24.89% and a negative net margin of 18.17%. The business’s revenue was down 4.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.69) EPS. As a group, sell-side analysts expect that Nevro will post -2.6 earnings per share for the current year.
About Nevro
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.
Recommended Stories
- Five stocks we like better than Nevro
- What Are the FAANG Stocks and Are They Good Investments?
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Stock Analyst Ratings and Canadian Analyst Ratings
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.